

10/560179
 IAP9 Rec'd PCT/PTO 09 DEC 2009

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	Not Yet Assigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Shigeru Akasofu
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	09857/0203535-US0

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ⁴ -Number-Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/RC/	CA	International Search Report for PCT/JP2004/008669 mailed September 21, 2004.	
/RC/	CB	XU, A. Jing et al., "Effect of 3-[1-(phenylmethyl)-4-piperidiny]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-1-propanone fumarate, a novel acetylcholinesterase inhibitor, on spatial cognitive impairment induced by chronic cerebral hypoperfusion in rats", Neuroscience Letters 331 (2002) pp.33-36.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

(W:1098 5710203)	/Renee Claytor/	Date Considered	06/21/2007
---------------------	-----------------	--------------------	------------



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/560,179
				Filing Date	December 9, 2005
				First Named Inventor	Shigeru Akasofu
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	09857/0203535-USO

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
/RC/	CA	"Protective effect of donepezil in a primary culture of rat cortical neurons exposed to oxygen-glucose deprivation", AKASOFU et al., European Journal of Pharmacology 472 (2003) pp. 57-63.			
/RC/	CB	"Huperzine B, a novel acetylcholinesterase inhibitor, attenuates hydrogen peroxide induced injury in PC12 cells", ZHANG et al., Neuroscience Letters 292 (2000), pp. 41-44.			
/RC/	CC	"Huperzine A and donepezil protect rat pheochromocytoma cells against oxygen-glucose deprivation", ZHOU et al., Neuroscience Letters 306 (2001) pp. 53-56.			
/RC/	CD	"Acetylcholinesterase Promotes the Aggregation of Amyloid- β -Peptide Fragments by Forming a Complex with the Growing Fibrils", ALVAREZ et al., J. Mol. Biol. (1997) 272, pp. 348-361.			
/RC/	CE	" β -Amyloid aggregation induced by human acetylcholinesterase: inhibition studies", BARTOLINI et al., Biochemical Pharmacology 65 (2003), pp. 407-416.			
/RC/	CF	"Increased expression of intranuclear AChE involved in apoptosis of SK-N-SH cells", YANG et al., Neuroscience Research 42 (2002), pp. 261-268.			
/RC/	CG	"Cerebro-protective effects of ENA713, a novel acetylcholinesterase inhibitor, in closed head injury in the rat", CHEN et al., Brain Research 784 (1998), pp. 18-24.			
/RC/	CH	"Protection against ischemic injury in primary cultured astrocytes of mouse cerebral cortex by bis(7)-tacrine, a novel anti-Alzheimer's agent", HAN et al., Neuroscience Letters 288 (2000), pp. 95-98.			
/RC/	CI	"Tacrine and donepezil attenuate the neurotoxic effect of A β (25-35) in rat PC12 cells", SVENSSON et al., NeuroReport 9, 1519-1522 (1998), pp. 1519-1522.			
/RC/	CJ	"Nicotinic Acetylcholine Receptor-Mediated Neuroprotection by Donepezil Against Glutamate Neurotoxicity in Rat Cortical Neurons", TAKADA et al., The Journal of Pharmacology and Experimental Therapeutic, Vol. 306, No. 2, 2003, pp. 772-777.			
/RC/	CK	"Randomized, Placebo-Controlled Trial of the Effects of Donepezil on Neuronal Markers and Hippocampal Volumes in Alzheimer's Disease", KRISHNAN, et al., Am. J. Psychiatry 2003, 160, pp. 2003-2011.			
/RC/	CL	"3-(40[(Benzyl(methyl)amino)methyl]-phenyl)-6, 7-dimethoxy-2H-2-chromenone (AP2238) Inhibits Both Acetylcholinesterase and Acetylcholinesterase-Induced β -Amyloid Aggregation:			
Examiner Signature	/Renee Claylor/			Date Considered	06/21/2007



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project (PTO/SB/08a/b) no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/560,179
				Filing Date	December 9, 2005
				First Named Inventor	Shigeru Akasofu
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	09857/0203535-USO

		A Dual Function Lead for Alzheimer's Disease Therapy", PIAZZI et al., J. Med. Chem. 2003, 46, pp. 2279-2282.	
/RC/	CM	"Stable Complexes Involving Acetylcholinesterase and Amyloid- β Peptide Change the Biochemical Properties of the Enzyme and Increase the Neurotoxicity of Alzheimer's Fibrils", ALVAREZ et al., The Journal of Neuroscience, May 1, 1998, 18(9), pp. 3213-3223.	
/RC/	CN	"Acetylcholinesterase induces neuronal cell loss, astrocyte hypertrophy and behavioral deficits in mammalian hippocampus", CHACON et al., Journal of Neurochemistry, 2003, 87, pp. 195-204.	
/RC/	CO	"Antisense oligonucleotide inhibition of acetylcholinesterase gene expression induces progenitor cell expansion and suppresses hematopoietic apoptosis, <i>ex vivo</i> ", SOREQ et al., Proc. Natl. Acad. Sci. USA, Vol. 91, pp. 7907-7911, August 1994.	
/RC/	CP	"Induction of acetylcholinesterase expression during apoptosis in various cell types", ZHANG et al., Cell Death and Differentiation (2002) 9, pp. 790-800.	
/RC/	CQ	"Huperzine A attenuates hydrogen peroxide-induced apoptosis by regulating expression of apoptosis-related genes in rat PC12 cells", WANG et al., Neuropharmacology and Neurotoxicology, Vol. 12, No. 12, August 28, 2001, pp. 2629-2634.	
/RC/	CR	"Use of Donepezil for Vascular Dementia: Preliminary Clinical Experience", MENDEZ et al., Clinical and Research Report, J. Neuropsychiatry Clin Neurosci 11: 2, Spring 1999, pp. 268-270.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Renee Claytor/	Date Considered	06/21/2007
-----------------------	-----------------	--------------------	------------